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that the high percentage of HER2-positive DCIS by
IHC may lack an underlying molecular basis. There-
fore, we would encourage exercising caution when
evaluating HER2 expression in DCIS by immunohisto-
chemistry.
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Sir: In non-small-cell lung cancer, higher pro-
grammed death-ligand 1 (PD-L1) expression by
tumour cells is associated with a better response to
immunotherapy.1 In routine clinical practice, a sub-
stantial number of thoracic oncologists tend to use
cytological techniques such as fine needle aspiration
(FNA) more often than biopsies. Cytopathological
analysis of pleural fluid, trans-oesophageal or bron-
chial FNA specimens and bronchial washes is fre-
quently performed, allowing tumour typing and a
concise evaluation for treatment targets. Up to now,
a limited number of studies have focused on histologi-
cal versus cytological correlation of PD-L1 immuno-
histochemistry. PD-L1 immunocytochemistry is
performed on formalin-fixed cytological material, and
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Ilie et al. demonstrated, for example, a correlation
coefficient of 0.898 on the Ventana Ultra platform.2,3
Routinely used fixatives in cytology are usually based
on methanol instead of formalin, which might nega-
tively affect PD-L1 staining intensity. To date, it
remains unclear whether a methanol-based fixative
without formalin fixation is suitable for predictive
immunocytochemical PD-L1 tests.
The use of FNA on a lobectomy sent for histological
examination allows fixation and processing of tumour
cytology concurrently with histology and staining of
PD-L1 of the same site. Paired FNA and standard his-
tological processing was performed on 64 lobectomies
with two routine immunohistochemical PD-L1
staining methods [22C3 (Agilent, Amstelveen, the
Netherlands) laboratory-developed test (LDT) and
SP263 CE-IVD assay (Roche, Almere, the Nether-
lands), both on Ventana Benchmark Ultra (Roche,
Almere, the Netherlands].4 The 22C3 LDT using the
Ventana platform was validated against the Dako
Pharm Dx assay using the Dako Link 48 platform.
During validation, the 22C3 LDT showed stronger
staining than the SP263 assay, which is in contrast to
the Blueprint results of Tsao et al.5 These differences in
staining intensities are probably attributable to the
platform used. In the Blueprint studies, 22C3 was
stained on the appropriate Dako platform, and
showed, just like SP263, a slightly less bright result
than that obtained with 22C3 on a Ventana
immunostainer. A further evaluation of the effects of
different fixatives on cytology for PD-L1 staining can
be performed with commercially available cell lines
with a gradual increase in staining intensity (Histo-
cyte, Newcastle upon Tyne, UK). Cell lines that are
grown and fixed for extended time periods with differ-
ent fixatives allow the detection of slight differences by
fixing of cells for longer and beyond routinely used
time periods.
PD-L1 expression was scored by two trained
pathologists in three tumour proportion categories:
<1%, 1–50% and >50% membranous staining of
tumour cells. After consensus between both patholo-
gists had been reached, the results were used to eval-
uate agreements between cytology and histology.
Weighted Cohen’s kappa on the PD-L1 scores for his-
tology and cytology of 64 lobectomy specimens was
calculated. For the 22C3 method, Cohen’s kappa
showed moderate agreement between PD-L1 staining
scores of histology and cytology (0.53), whereas the
SP263 method showed substantial agreement (0.67).
A striking difference was found between a subgroup
consisting of agar cell blocks fixed in 10% buffered
formalin and a subgroup consisting of Cellient cell
blocks (Hologic, Zaventem, Belgium) fixed in metha-
nol-based CytoLyt/PreservCyt (Hologic) (Figure 1).
PD-L1 staining in Cellient cell blocks showed fair to
moderate agreement between cytology and histology,
with weighted kappas of 0.36 for 22C3 (n = 38) and
0.60 for SP263 (n = 37). PD-L1 staining in agar cell
blocks showed substantial agreement between cytol-
ogy and histology [weighted kappa for 22C3 of 0.77
(n = 26), and weighted kappa for SP263 of 0.76
(n = 26)]. Further evaluation of fixation effects was
performed with cell lines. A Cellient cell block
0%















PD-L1 staining in cytology
Figure 1. Programmed death-ligand 1 (22C3 laboratory-developed test on Ventana Benchmark Ultra) staining, categorised in three bins
comparing agar cell blocks (n = 28) and Cellient cell blocks (n = 39) with their histological counterparts.
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containing cells that were fixed for Σ2 h in CytoLyt
showed lower staining intensity than formalin-fixed
cells. Longer fixation times resulted in similar find-
ings, with a further decrease in staining intensity
after 48–72 h when methanol fixation was used
instead of formalin (Figure 2).
In conclusion, our results indicate that cytology
can be used reliably for determination of PD-L1
expression when formalin fixation is used. Moreover,
PD-L1-expressing cell lines confirmed the deleterious
effect of methanol fixation, making the routinely
used CytoLyt/PreservCyt fixatives in the Cellient
technique less appropriate for predictive testing for
immunotherapy.
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Sir: Thymic epithelial tumours (TET) are rare malig-









Figure 2. Decreasing Programmed death-ligand 1 expression with increasing fixation time in a cell line: 2 h (A,E) or 24 h (C,G) of fixation
in formalin, and 2 h (B,F) or 24 h (D,H) of fixation in CytoLyt. A–D, SP263 CE-IVD assay. E–H, 22C3 laboratory-developed test.
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